March 30, 2005
Boston, MA- While aspirin is
used in the treatment of myocardial infarction and as a
secondary prevention in cardiovascular disease, its role as a
primary form of prevention remained unknown. In the Women’s
Health Study, Paul Ridker et al from Brigham and Women’s
Hospital at Harvard Medical School, evaluated the lowest dose of
aspirin that would have a cardioprotective effect. The study was
published in the March 31,2005 issue of The New England Journal
of Medicine and found that aspirin lowered the risk of stroke
without affecting the risk of myocardial infarction or death
from cardiovascular causes.
Evidence of the effects of
aspirin in women is necessary because cardiovascular disease is
the leading cause of death in both men and women. The effects of
aspirin in women and its prophylactic use for stroke and
myocardial infarction is the primary concern in the Women’s
Health Study. The study randomly assigned 39,876 initially
healthy women 45 years of age or older to receive 100 mg of
aspirin on alternate days or placebo. They were monitored for 10
years for a first major cardiovascular event, such as nonfatal
myocardial infarction, stoke or death from cardiovascular
causes.
Results from follow-up indicate
477 major cardiovascular events in the aspirin group, as
compared to 522 in the placebo group, resulting in a reduction
of 9 percent (relative risk, 0.91; 95 percent confidence
interval, 0.80-1.03). There was a 17 percent reduction in the
risk of stoke in the aspirin group as compared to placebo
(relative risk, 0.83; 95 percent confidence interval,0.69 to
0.99; P=0.04), owing to a 24 percent reduction in the risk of
ischemic stroke (relative risk, 0.76; 95 percent confidence
interval 0.63 to 0.93; P=0.009). The increase in risk of
hemorrhagic stroke was non-significant (relative risk, 1.24; 95
percent confidence interval, 0.82 to 1.87; P=0.31). Aspirin had
no significant effect on the risk of fatal or nonfatal
myocardial infarction (Relative Risk, 1.02; 95 percent
confidence interval 0.84 to 1.25; P=0.83) or death from
cardiovascular causes (relative risk, 0.95; 95 percent
confidence interval, 0.74 to 1.22; P=0.68). It was significant
that gastrointestinal bleeding requiring transfusion was more
frequent in the aspirin group than in the placebo group
(relative risk 1.4; 95 percent confidence interval, 1.07 to
1.83; P=0.02).
Overall, in this large,
placebo-controlled, primary-prevention trial, a prophylactic
dose of 100 mg every other day is associated with a reduction of
total stroke and ischemic stroke, a nonsignificant reduction in
the risk of major cardiovascular events, a nonsignificant
increase in the risk of hemorrhagic stoke and non significant
effect on the risk of myocardial infarction or death from
cardiovascular causes.
Co-authors:
Nancy R. Cook, Sc.D., I-Min Lee, M.B., B.S., David Gordon, M.A.,
J. Michael Gaziano, M.D., Joann E. Manson, M.D., Charles H.
Hennekens, M.D., and Julie E. Buring, Sc.D. |